<DOC>
	<DOCNO>NCT00989573</DOCNO>
	<brief_summary>The purpose study verify safety efficacy OPC-6535 determine optimal dose once-daily oral administration OPC-6535 25 50 mg placebo 8 week combination base treatment ( either fix oral dose 5-aminosalicylic acid [ 5-ASA ] fix oral dose 5-ASA plus enteral nutrition ) 180 patient active Crohn 's disease .</brief_summary>
	<brief_title>A Dose-finding Confirmatory Trial OPC-6535 Patients With Active Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Primary lesion either small intestine large intestine Creactive protein ( CRP ) level upper limit normal range Patients receive 5ASA formulation ( oral mesalazine ) fix dose 2.25 g/day high ( exceed approve dose ) fix dose regimen Patients receive enteral nutrition receive enteral nutrition fix intake 1200 kcal/day le Patients uncontrolled external fistula ( include anal fistula ) Patients history total proctocolectomy subtotal colectomy Patients short bowel syndrome Patients artificial anus Patients serious infectious disease ( intraabdominal abscess , etc ) Patients malignant tumor Female patient pregnant , lactate , possibly pregnant , wish become pregnant trial period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>